Should health insurers target prevention of cardiovascular disease?: a cost-effectiveness analysis of an individualised programme in Germany based on routine data

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  Shah Ebrahim,et al.  [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[3]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[4]  K. Bestehorn,et al.  Disease management programs in type 2 diabetes: quality of care. , 2011, The American journal of managed care.

[5]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[6]  S. Bayliss,et al.  Community programs for the prevention of cardiovascular disease: a systematic review. , 2010, American journal of epidemiology.

[7]  S. Stock,et al.  Financial incentives in the German Statutory Health Insurance: new findings, new questions. , 2010, Health policy.

[8]  H. Bueno,et al.  Differences in medical treatment of chronic coronary heart disease patients according to medical specialities. , 2009, Cardiovascular therapeutics.

[9]  S. Allender,et al.  Cardiovascular disease in Europe , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[10]  Kenneth A. Brown,et al.  Problems and Perspectives , 2009, The Search for Security in the Pacific 1901-1914.

[11]  R. Holle,et al.  Disease management programmes for patients with coronary heart disease--an empirical study of German programmes. , 2008, Health policy.

[12]  Christian Weber,et al.  German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  M. Redaélli,et al.  Preliminary analysis of short term financial implications of a prevention bonus program: First results from the German statutory health insurance , 2008, International Journal of Public Health.

[14]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[15]  T Schelhase,et al.  [Mortality statistics in Germany. Problems and perspectives]. , 2007, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

[16]  Torsten Schelhase,et al.  Die Todesursachenstatistik in Deutschland , 2007, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[17]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[18]  U. Keil,et al.  Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[19]  S. Silber,et al.  Können Medikamente frei setzende Koronarstents eine Bypassoperation ersetzen? , 2005, Herz Kardiovaskuläre Erkrankungen.

[20]  S. Silber,et al.  [Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system]. , 2005, Herz.

[21]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[22]  B. McCullough,et al.  Regression analysis of variates observed on (0, 1): percentages, proportions and fractions , 2003 .

[23]  G. Assmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.

[24]  P. Armstrong,et al.  Randomised trials of secondary prevention programmes in coronary heart disease: systematic review , 2001, BMJ : British Medical Journal.

[25]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[26]  A. Go,et al.  A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States. , 2000, The American journal of medicine.

[27]  C. Normand,et al.  Strategies for reducing coronary risk factors in primary care: which is most cost effective? , 1995, BMJ.

[28]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[29]  B. Squires.  Methods for the Economic Evaluation of Health Care Programmes. , 1987 .

[30]  Peter Pagel,et al.  Gesundheit , 2021, Arbeit und Altern.

[31]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[32]  J. Pearl.  Causality: Models, Reasoning and Inference , 2000 .

[33]  L. Davies.  ECONOMIC EVALUATION IN CLINICAL TRIALS , 1998 .